Biophan CEO to Highlight Breakthrough Nanotechnology-Based Biomedical Applications at Foresight Institute Conference; Presentation to Detail Company's Strategy to Leverage Intellectual Property Portfolio.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation medical technology, has announced that representatives of the Company will present the Company's breakthrough nanotechnology-based healthcare applications and its business strategies to monetize its innovations at the 13th Foresight Conference on Advanced Nanotechnology, scheduled to take place October 22 - 27, in San Francisco, CA.

An update on the Company's breakthrough nanotechnology innovations will be presented, including solutions to improve safety and effectiveness of Magnetic Resonance Imaging (MRI) in healthcare, unique thermoelectric battery technology designed to power implantable medical devices, advanced contrast agents for medical imaging, and next-generation applications for the drug delivery and drug-elution marketplace. This presentation is scheduled for October 25, at 12:30 p.m. Pacific.

In addition, the Company's business strategy will be presented in the conference's "Public Equity Roundtable" presentation, scheduled for 5:45 p.m. on October 25.

"The Foresight conference will provide valuable investor and industry exposure for our array of innovative nanotechnology applications," said Mr. Weiner. "Our business plan is designed to leverage these next-generation solutions to enable a range of products for various healthcare market segments, such as advanced drug-delivery systems, an implantable biothermal power supply, enhanced MRI imaging, and others."

The Company recently launched an initiative to expand its presence in cardiovascular diagnostic and therapeutic devices, one of the fastest-growing segments of the biomedical industry, with the potential to reach nearly $28 billion before the end of this decade.

About the Foresight Nanotech Institute

Foresight Nanotech Institute's mission is to ensure the beneficial implementation of nanotechnology. Founded in 1986, it was the first organization to educate society about the benefits and risks of nanotechnology. At that time the Institute's focus was on preparing society for nanotechnology, then a little known science and technology. Today, with the basic framework of public understanding in place, the Institute is focusing on advancing beneficial nanotechnology. Their efforts are turned to guiding nanotechnology research, public policy and education to address six major challenges that humanity faces. The six Foresight Nanotechnology Challenges are the framework for their work. This work is accomplished by providing balanced, accurate and timely information to help society understand and prepare for nanotechnology through public policy activities, publications, guidelines, networking events, tutorials, conferences, roadmaps, and prizes. The Institute works closely with governments, multi-national organizations, NGOs (non-governmental organizations), environmental groups, the policy community, professional associations, and civic sector organizations to achieve their goal of broad based nanotechnology education and public policy improvement. For more information on the conference, please visit

http://www.foresight.org/conference2005/

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 42 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol "BTN." For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements 

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.